FDA
-
-
-
-
-
-
-
Laidlaw Starts Kazia Therapeutics (KZIA) at Buy
-
-
-
-
-
-
-
Kazia presents breast cancer trial data at medical conference
-
-
-
-
-
-
-
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
-
-
-
-
-
-
-
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Sells IP and Trademarks Rights for Cantrixil for $1M
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Announces $2.0 Million Registered Direct Offering
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metasta
-
322,978 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

